- 605 views
From the exponential growth of the “modern” biotechnology industry in the 1990’s the creation of Contract Manufacturing Organizations (CMOs) has followed to supply the increasing needs of ...
From the exponential growth of the “modern” biotechnology industry in the 1990’s the creation of Contract Manufacturing Organizations (CMOs) has followed to supply the increasing needs of production capacity and cost savings. Yet at that time, only a few CMOs existed. Back then in the pharmaceutical industry, only 5% of new drug approvals by the FDA were issued from biotechnology companies and in the industrial biotechnology sector most enzymes were still produced by extraction or by chemical synthesis.
166 contract biomanufacturing Organizations were identified in the European biomanufacturing market accounting for 229 production sites located in Europe.
Two kinds of CMOs exist in Europe: 73% “Multipurpose” CMOs and 27% AB-only CMOs for custom monoclonal and polyclonal antibody manufacturing.
49% of Biomanufacturing CMOs are located in Western Europe. More than half of all AB-only biomanufacturers (52%) are located in UK and France.
Four main expression systems are used by contract biomanufacturing organizations: microbial, mammalian, transgenic animals and plant cells. Microbial platform still comes out on top of expression system used in Contract biomanufacturing with more than 83% of utilization by Multi-P CMOs, followed by mammalian cell culture (35%).
- Total Views
- Views on SlideShare
- Embed Views